Potential Role of the Triple Receptor Agonist Retatrutide in Antipsychotic-Associated Metabolic Dysfunction Among Clozapine- and Olanzapine-Treated Schizophrenia Spectrum Disorders: A Narrative Review and Theoretical Framework
Open Access
- 31 August 2026
- journal article
- review article
- Published by MDPI AG in Biomedicines
- Vol. 14 (9) , 1957
Abstract
Antipsychotic-associated metabolic dysfunction contributes substantially to cardiometabolic morbidity and premature mortality in schizophrenia spectrum disorders, with the greatest burden among patients treated with clozapine and olanzapine. This review focuses on patients with schizophrenia spectrum disorders receiving these two agents, in whom the relevant psychiatric evidence is concentrated. Existing pharmacological interventions, including metformin and glucagon-like peptide-1 receptor agonists (GLP-1RAs), produce clinically meaningful but often incomplete benefits. Retatrutide (LY3437943) is a once-weekly triple agonist of the GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors that produced a mean body-weight reduction of 24.2% at 48 weeks under the efficacy estimand in a Phase 2 obesity trial; company-reported Phase 3 results from four trials, not yet peer-reviewed, describe reductions of up to 28.7%. This narrative review examines the rationale for investigating retatrutide in this setting, drawing on retatrutide trials in non-psychiatric populations, the pathophysiology of antipsychotic-induced weight gain, and emerging evidence for incretin-based therapies in antipsychotic-treated populations. The glucagon component is of particular mechanistic interest because it increases basal energy expenditure, a pathway not engaged by mono- or dual agonists; whether this could partially compensate for the reduced physical activity associated with antipsychotic-related sedation is untested and is presented here solely as a hypothesis. Indirect support comes from randomized trials and meta-analyses of GLP-1RAs in clozapine- or olanzapine-treated patients, which report reductions in body weight and glycemic impairment without evidence of worsening psychotic symptoms. No trial has evaluated retatrutide in an antipsychotic-treated population. Future studies should therefore characterize gastrointestinal tolerability, potential interaction with clozapine-associated gastrointestinal hypomotility, possible effects on clozapine and olanzapine exposure, adherence and feasibility, and the dysesthesia observed in retatrutide trials, which was dose-related in most but not all trials. Dedicated randomized controlled trials are needed to determine the efficacy and safety of retatrutide in patients with schizophrenia spectrum disorders receiving clozapine or olanzapine.Keywords
This publication has 128 references indexed in Scilit:
- Pharmacological Interventions for Weight Reduction in Patients With Schizophrenia Treated With AntipsychoticsJAMA Psychiatry, 2026
- Semaglutide and Early-Stage Metabolic Abnormalities in Individuals With Schizophrenia Spectrum DisordersJAMA Psychiatry, 2026
- Semaglutide Treatment of Antipsychotic-Treated Patients With Schizophrenia, Prediabetes, and ObesityJAMA Psychiatry, 2025
- Suicide and Self-Harm Events With GLP-1 Receptor Agonists in Adults With Diabetes or ObesityJAMA Psychiatry, 2025
- Glucagon-Like Peptide 1 Receptor Agonists and Mental HealthJAMA Psychiatry, 2025
- Pharmacological interventions for prevention of weight gain in people with schizophreniaCochrane Database of Systematic Reviews, 2022
- Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum DisorderJAMA Psychiatry, 2017
- Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategiesWorld Psychiatry, 2013
- Systematic Review of Early Cardiometabolic Outcomes of the First Treated Episode of PsychosisArchives of General Psychiatry, 2011
- Clozapine Treatment for Suicidality in SchizophreniaInternational Suicide Prevention Trial (InterSePT)Archives of General Psychiatry, 2003